What's Happening?
Leica Biosystems, a subsidiary of Danaher Corporation, has announced the U.S. launch of its new Aperio GT Elite scanner and Aperio iQC software. These innovations are designed to improve digital pathology workflows by increasing speed and accuracy in slide
processing and review. The Aperio GT Elite scanner is engineered for high-throughput environments, capable of processing 103 slides per hour and scanning each slide in as little as 22 seconds. It features SmartScanTM barcode-driven automation to minimize manual handling. The accompanying Aperio iQC software integrates AI-powered quality control directly into the scanning process, automatically detecting imaging artifacts and alerting users to potential issues. This technology aims to reduce manual rework and improve the consistency of image quality, ultimately advancing cancer research and diagnostics.
Why It's Important?
The introduction of the Aperio GT Elite scanner and Aperio iQC software is significant for the field of digital pathology, particularly in cancer diagnostics. By automating quality control and reducing manual intervention, these tools can help laboratories operate more efficiently and accurately. This is crucial in the context of a global shortage of qualified histotechnologists, as it allows existing staff to focus on more complex tasks. The enhanced speed and accuracy of these tools can lead to faster diagnoses and potentially better patient outcomes. Additionally, by reducing operational expenses associated with manual quality control, laboratories can allocate resources more effectively, supporting broader scientific research and innovation.
What's Next?
Leica Biosystems plans to further integrate these technologies into the computational pathology ecosystem, enhancing their portfolio of end-to-end solutions. The company is hosting a webinar on April 24, 2026, to provide more insights into the Aperio iQC software and its rescan technology. This event will offer user perspectives and demonstrate the software's capabilities. As these technologies gain traction, they may set new standards in digital pathology, influencing how laboratories worldwide approach cancer diagnostics and research.
